Skip to main content

Table 6 This table depicts pertinent baseline characteristic and selected admitting diagnoses of patients enrolled into the restrictive arm of the TRICC trial [15] and those in the placebo arm of the randomized controlled trial of rHuEPO treatment of critically ill patients [16], the groups from which our main input parameters were derived*.

From: Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation

  Restrictive strategy, TRICC (N = 418) Placebo, rHuEPO RCT (n = 652)
Age, mean ± SD, years 57.1 ± 18.1 51 ± 19.4
Gender male 64% 63.7%
APACHE II score, mean ± SD 20.9 ± 7.3 19.6 ± 7.99
Proportion post-operative 39%a 42.5%
Proportion trauma 20% 48.5%
Proportion sepsis/SIRS 6% 7.7%b
Proportion respiratory disease 28% 25%c
Proportion cardiovascular disease 18% 5.4%
  1. *TRICC, Transfusion Requirements in Critical Care15; rHuEPO, recombinant human erythropoietin; RCT, randomized controlled trial; SD, standard deviation; APACHE, Acute Physiology and Chronic Health Evaluation; SIRS, systemic inflammatory response syndrome.
  2. aThis is the number corresponding to proportion of patients with location before ICU admission being the operating room or the recovery room15
  3. bThis was calculated by adding together the proportion of sepsis and SIRS patients16
  4. cThis was calculated by adding together the proportion of patients with pneumonia, ARDS and other respiratory diagnoses16